Mei Pharma, INC 8-K filings

MEI Pharma is focusing on its voruciclib program after encouraging clinical data, while also advancing a new formulation for ME-344.

MEI Pharma has entered into a sales agreement to potentially sell up to $25 million of its common stock through JonesTrading, initially offering up to $10.3 million due to public float limitations.

MEI Pharma announced its second quarter fiscal year 2024 results, highlighting progress in clinical trials for voruciclib and ME-344, and a decrease in operating expenses.

MEI Pharma has entered into a new employment agreement with its Chief Medical Officer, Dr. Richard Ghalie, updating his compensation and severance terms.